The merger is complete; PCRX shares will be delisted and deregistered. Holders who did not tender should contact their broker or the depositary to receive the $36.50 per share consideration. No further trading or corporate events are expected.
PCRX drugs
PCRX drug pipeline →Price Chart
Executive Summary
Pacira BioSciences filed Amendment No. 3 to its Schedule 14D-9 confirming that Viatris's tender offer expired on November 16, 2026, with 32,929,780 shares (66.46%) validly tendered. All conditions were satisfied, and on November 17, 2026, the merger was consummated, making Pacira a wholly owned subsidiary of Viatris at $36.50 per share in cash. The shares will be delisted from Nasdaq.
Key Facts
- Tender offer expired November 16, 2026 with 32,929,780 shares (66.46%) validly tendered
- Offer price: $36.50 per share in cash
- All conditions satisfied or waived; Purchaser accepted shares on November 17, 2026
- Merger consummated on November 17, 2026 under Section 251(h) of DGCL
- Pacira became a wholly owned subsidiary of Viatris
- Shares to be delisted from Nasdaq Global Select Market and deregistered
Financial Impact
Acquisition of Pacira for $36.50 per share in cash; total consideration based on ~49.5M shares outstanding (implied ~$1.8B enterprise value)
Risk Factors
- Potential appraisal/valuation proceedings by stockholders who perfected dissenters' rights
- Delisting and deregistration eliminate public market liquidity
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 4 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| SC 14D-9/A Filing (Primary) | 0001140361-26-044349 |
| Document: 0001140361-26-044349-index-headers.html | 0001140361-26-044349 |
| Document: 0001140361-26-044349-index.html | 0001140361-26-044349 |
| Document: 0001140361-26-044349.txt | 0001140361-26-044349 |
Track record
33 reports on PCRX
5 of 7 bullish or bearish reports moved the stock their way by T+20. Best: +42.26% at T+60 after the Aug 6, 2026 report. 8 of 9 went positive at some point.
Filters
- Nov 17, 20264d ago 8-K Mixed 8/10 Entry $36.48 Now $36.48 −0.00% settles Dec 16
- Nov 17, 20264d ago SC 14D-9/A Mixed 8/10 Viewing Entry $36.48 Now $36.48 −0.00% settles Dec 16
- Nov 17, 20264d ago SC TO-T/A Mixed 7/10 Entry $36.48 Now $36.48 −0.00% settles Dec 16
- Nov 17, 20264d ago 25-NSE Neutral 1/10 Entry $36.48 Now $36.48 −0.00% settles Dec 16
- Nov 12, 20269d ago 8-K Bearish 6/10 Entry $36.46 Now $36.48 −0.05% settles Dec 14
- Nov 12, 20269d ago SC TO-T/A Mixed 7/10 Entry $36.46 Now $36.48 +0.05% settles Dec 14
- Nov 12, 20269d ago SC 14D-9/A Neutral 3/10 Entry $36.46 Now $36.48 +0.05% settles Dec 14
- Nov 5, 202616d ago 8-K Neutral 5/10 Entry $36.43 Now $36.48 +0.14% settles Dec 7
- Nov 3, 202618d ago SC 14D-9/A Neutral 3/10 Entry $36.40 Now $36.48 +0.22% settles Dec 3
- Oct 30, 202622d ago SC 13G/A Neutral 2/10 Entry $36.39 Now $36.48 +0.25% settles Nov 30
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers